Cargando…

Development and Validation of a Serologic Test Panel for Detection of Powassan Virus Infection in U.S. Patients Residing in Regions Where Lyme Disease Is Endemic

Powassan virus (POWV) is an emerging tick-borne arbovirus presenting a public health threat in North America. POWV lineage II, also known as deer tick virus, is the strain of the virus most frequently found in Ixodes scapularis ticks and is implicated in most cases of POWV encephalitis in the United...

Descripción completa

Detalles Bibliográficos
Autores principales: Thomm, Angela M., Schotthoefer, Anna M., Dupuis, Alan P., Kramer, Laura D., Frost, Holly M., Fritsche, Thomas R., Harrington, Yvette A., Knox, Konstance K., Kehl, Sue C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5760746/
https://www.ncbi.nlm.nih.gov/pubmed/29359181
http://dx.doi.org/10.1128/mSphere.00467-17
_version_ 1783291424825933824
author Thomm, Angela M.
Schotthoefer, Anna M.
Dupuis, Alan P.
Kramer, Laura D.
Frost, Holly M.
Fritsche, Thomas R.
Harrington, Yvette A.
Knox, Konstance K.
Kehl, Sue C.
author_facet Thomm, Angela M.
Schotthoefer, Anna M.
Dupuis, Alan P.
Kramer, Laura D.
Frost, Holly M.
Fritsche, Thomas R.
Harrington, Yvette A.
Knox, Konstance K.
Kehl, Sue C.
author_sort Thomm, Angela M.
collection PubMed
description Powassan virus (POWV) is an emerging tick-borne arbovirus presenting a public health threat in North America. POWV lineage II, also known as deer tick virus, is the strain of the virus most frequently found in Ixodes scapularis ticks and is implicated in most cases of POWV encephalitis in the United States. Currently, no commercial tests are available to detect POWV exposure in tick-borne disease (TBD) patients. We describe here the development and analytical validation of a serologic test panel to detect POWV infections. The panel uses an indirect enzyme immunoassay (EIA) to screen. EIA-positive samples reflex to a laboratory-developed, POWV-specific immunofluorescence assay (IFA). The analytical sensitivity of the test panel was 89%, and the limit of detection was a plaque reduction neutralization test (PRNT) titer of 1:20. The analytical specificity was 100% for the IgM assay and 65% for the IgG assay when heterologous-flavivirus-positive samples were tested. On samples collected from regions where Lyme disease is endemic, seroprevalence for POWV in TBD samples was 9.4% (10 of 106) versus 2% when tested with non-TBD samples (2 of 100, P = 0.034). No evidence of POWV infection was seen in samples collected from a region where Lyme disease was not endemic (0 of 22). This test panel provides a sensitive and specific platform for detecting a serologic response to POWV early in the course of infection when neutralizing antibodies may not be detectable. Combined with clinical history, the panel is an effective tool for identifying acute POWV infection. IMPORTANCE Approximately 100 cases of POWV disease were reported in the United States over the past 10 years. Most cases have occurred in the Northeast (52) and Great Lakes (45) regions (https://www.cdc.gov/powassan/statistics.html). The prevalence of POWV in ticks and mammals is increasing, and POWV poses an increasing threat in a greater geographical range. In areas of the Northeast and Midwest where Lyme disease is endemic, POWV testing is recommended for patients with a recent tick bite, patients with Lyme disease who have been treated with antibiotics, or patients with a tick exposure who have tested negative for Lyme disease or other tick-borne illnesses and have persistent symptoms consistent with posttreatment Lyme disease. Testing could also benefit patients with tick exposure and unexplained neurologic symptoms and chronic fatigue syndrome (CFS) patients with known tick exposure. Until now, diagnostic testing for Powassan virus has not been commercially available and has been limited to patients presenting with severe, neurologic complications. The lack of routine testing for Powassan virus in patients with suspected tick-borne disease means that little information is available regarding the overall prevalence of the virus and the full spectrum of clinical symptoms associated with infection. As Ixodes scapularis is the tick vector for Powassan virus and multiple other tick-borne pathogens, including the Lyme disease bacterium, Borrelia burgdorferi, the clinical presentations and long-term outcomes of Powassan virus infection and concurrent infection with other tick-borne disease pathogens remain unknown.
format Online
Article
Text
id pubmed-5760746
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher American Society for Microbiology
record_format MEDLINE/PubMed
spelling pubmed-57607462018-01-22 Development and Validation of a Serologic Test Panel for Detection of Powassan Virus Infection in U.S. Patients Residing in Regions Where Lyme Disease Is Endemic Thomm, Angela M. Schotthoefer, Anna M. Dupuis, Alan P. Kramer, Laura D. Frost, Holly M. Fritsche, Thomas R. Harrington, Yvette A. Knox, Konstance K. Kehl, Sue C. mSphere Research Article Powassan virus (POWV) is an emerging tick-borne arbovirus presenting a public health threat in North America. POWV lineage II, also known as deer tick virus, is the strain of the virus most frequently found in Ixodes scapularis ticks and is implicated in most cases of POWV encephalitis in the United States. Currently, no commercial tests are available to detect POWV exposure in tick-borne disease (TBD) patients. We describe here the development and analytical validation of a serologic test panel to detect POWV infections. The panel uses an indirect enzyme immunoassay (EIA) to screen. EIA-positive samples reflex to a laboratory-developed, POWV-specific immunofluorescence assay (IFA). The analytical sensitivity of the test panel was 89%, and the limit of detection was a plaque reduction neutralization test (PRNT) titer of 1:20. The analytical specificity was 100% for the IgM assay and 65% for the IgG assay when heterologous-flavivirus-positive samples were tested. On samples collected from regions where Lyme disease is endemic, seroprevalence for POWV in TBD samples was 9.4% (10 of 106) versus 2% when tested with non-TBD samples (2 of 100, P = 0.034). No evidence of POWV infection was seen in samples collected from a region where Lyme disease was not endemic (0 of 22). This test panel provides a sensitive and specific platform for detecting a serologic response to POWV early in the course of infection when neutralizing antibodies may not be detectable. Combined with clinical history, the panel is an effective tool for identifying acute POWV infection. IMPORTANCE Approximately 100 cases of POWV disease were reported in the United States over the past 10 years. Most cases have occurred in the Northeast (52) and Great Lakes (45) regions (https://www.cdc.gov/powassan/statistics.html). The prevalence of POWV in ticks and mammals is increasing, and POWV poses an increasing threat in a greater geographical range. In areas of the Northeast and Midwest where Lyme disease is endemic, POWV testing is recommended for patients with a recent tick bite, patients with Lyme disease who have been treated with antibiotics, or patients with a tick exposure who have tested negative for Lyme disease or other tick-borne illnesses and have persistent symptoms consistent with posttreatment Lyme disease. Testing could also benefit patients with tick exposure and unexplained neurologic symptoms and chronic fatigue syndrome (CFS) patients with known tick exposure. Until now, diagnostic testing for Powassan virus has not been commercially available and has been limited to patients presenting with severe, neurologic complications. The lack of routine testing for Powassan virus in patients with suspected tick-borne disease means that little information is available regarding the overall prevalence of the virus and the full spectrum of clinical symptoms associated with infection. As Ixodes scapularis is the tick vector for Powassan virus and multiple other tick-borne pathogens, including the Lyme disease bacterium, Borrelia burgdorferi, the clinical presentations and long-term outcomes of Powassan virus infection and concurrent infection with other tick-borne disease pathogens remain unknown. American Society for Microbiology 2018-01-10 /pmc/articles/PMC5760746/ /pubmed/29359181 http://dx.doi.org/10.1128/mSphere.00467-17 Text en Copyright © 2018 Thomm et al. https://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Research Article
Thomm, Angela M.
Schotthoefer, Anna M.
Dupuis, Alan P.
Kramer, Laura D.
Frost, Holly M.
Fritsche, Thomas R.
Harrington, Yvette A.
Knox, Konstance K.
Kehl, Sue C.
Development and Validation of a Serologic Test Panel for Detection of Powassan Virus Infection in U.S. Patients Residing in Regions Where Lyme Disease Is Endemic
title Development and Validation of a Serologic Test Panel for Detection of Powassan Virus Infection in U.S. Patients Residing in Regions Where Lyme Disease Is Endemic
title_full Development and Validation of a Serologic Test Panel for Detection of Powassan Virus Infection in U.S. Patients Residing in Regions Where Lyme Disease Is Endemic
title_fullStr Development and Validation of a Serologic Test Panel for Detection of Powassan Virus Infection in U.S. Patients Residing in Regions Where Lyme Disease Is Endemic
title_full_unstemmed Development and Validation of a Serologic Test Panel for Detection of Powassan Virus Infection in U.S. Patients Residing in Regions Where Lyme Disease Is Endemic
title_short Development and Validation of a Serologic Test Panel for Detection of Powassan Virus Infection in U.S. Patients Residing in Regions Where Lyme Disease Is Endemic
title_sort development and validation of a serologic test panel for detection of powassan virus infection in u.s. patients residing in regions where lyme disease is endemic
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5760746/
https://www.ncbi.nlm.nih.gov/pubmed/29359181
http://dx.doi.org/10.1128/mSphere.00467-17
work_keys_str_mv AT thommangelam developmentandvalidationofaserologictestpanelfordetectionofpowassanvirusinfectioninuspatientsresidinginregionswherelymediseaseisendemic
AT schotthoeferannam developmentandvalidationofaserologictestpanelfordetectionofpowassanvirusinfectioninuspatientsresidinginregionswherelymediseaseisendemic
AT dupuisalanp developmentandvalidationofaserologictestpanelfordetectionofpowassanvirusinfectioninuspatientsresidinginregionswherelymediseaseisendemic
AT kramerlaurad developmentandvalidationofaserologictestpanelfordetectionofpowassanvirusinfectioninuspatientsresidinginregionswherelymediseaseisendemic
AT frosthollym developmentandvalidationofaserologictestpanelfordetectionofpowassanvirusinfectioninuspatientsresidinginregionswherelymediseaseisendemic
AT fritschethomasr developmentandvalidationofaserologictestpanelfordetectionofpowassanvirusinfectioninuspatientsresidinginregionswherelymediseaseisendemic
AT harringtonyvettea developmentandvalidationofaserologictestpanelfordetectionofpowassanvirusinfectioninuspatientsresidinginregionswherelymediseaseisendemic
AT knoxkonstancek developmentandvalidationofaserologictestpanelfordetectionofpowassanvirusinfectioninuspatientsresidinginregionswherelymediseaseisendemic
AT kehlsuec developmentandvalidationofaserologictestpanelfordetectionofpowassanvirusinfectioninuspatientsresidinginregionswherelymediseaseisendemic